From StockStory.org: 2025-02-09 08:04:14

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting its earnings tomorrow. Last quarter, the company beat revenue expectations by 3.2%, reporting $2.77 billion, an 11.6% increase year on year. Analysts expect this quarter’s revenue to grow 10.3% to $2.78 billion, with adjusted earnings of $4.02 per share. Vertex Pharmaceuticals has missed revenue estimates three times in the last two years. Peers like AbbVie and Amgen have reported strong results, with revenue growth of 5.6% and 10.9% respectively. Vertex Pharmaceuticals stock is up 13.5% over the last month, with an average analyst price target of $490.59.



Read more at StockStory.org: Vertex Pharmaceuticals (VRTX) Q4 Earnings Report Preview: What To Look For